Emergence of piperacillin/tazobactam-resistant Escherichia coli [5]

Intensive Care Medicine

Volumn 26, Issue 10, 2000, Pages 1584-

  Mohammedi, I ^a   Tigaud, S ^a   Tournadre, J P ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ESCHERICHIA COLI; GRAM NEGATIVE INFECTION; HUMAN; INTENSIVE CARE; LETTER;

ANTIBIOTICS, COMBINED; BETA-LACTAMASES; COMMUNICABLE DISEASES, EMERGING; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; ESCHERICHIA COLI INFECTIONS; FRANCE; HUMAN; INFECTION CONTROL; INTENSIVE CARE UNITS; PATIENT SELECTION; PENICILLANIC ACID; PENICILLINS; PIPERACILLIN;

EID: 0033783559     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001340000659     Document Type: Letter

References (5)

1. Piperacillin/tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections
2. Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection
3. Escherichia coli: Epidemiology and analysis of risk factors for infections caused by resistant strains
4. Risk factors for recovery of ampicillin/sulbactam-resistant Escherichia coli in hospitalized patients
5. Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents